Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (11524)	11/20/1997 1:48:00 AM
From: Proton	Read Replies (1) \| Respond to of 32384

BTW, the drug is Prandin (not "<<<"), and I do think the ALRI discussion is quite on topic, and I appreciate it. Pý

To: Proton who wrote (11524)	11/20/1997 1:06:00 PM
From: Proton	Respond to of 32384

Re: Hate to be Pushy Here... ... but I really would like some insights from all of you -- irrespective of your status with LGND -- regarding Novo's Prandin for Type II diabetes: dljdirect.com Perhaps this has been hashed over by all of you, and you can just post links to the relevant messages. However, given the excitement we're all supposed to be feeling about Targretin and the worldwide growth of diabetes, one should think the Prandin approval is an important competitive development. What turned my head was the fact that Prandin got expedited review status. Now, with all due respect, please spare me any lectures about the fact that expedited review (or lack thereof) has nothing to do with ultimate efficacy, scientific breakthrough, or revenue potential. Most posters here, including myself, understand that. However, a glance at the list of clinical trials and recent and pending approvals gives one the sense that the market captivation with diabetes therapies may be diminished by the time Targretin actually gets to NDA. As always, I appreciate the insights I find on this thread. Any thoughts on Prandin? Pý p.s. one of my messages early this a.m. had a link to an excellent Reuters article on Prandin and the current state of the diabetes market.